Top

Published in:

01-10-2009 | MS Treatment

New oral drugs for multiple sclerosis

Authors: Claudio Gasperini, S. Ruggieri

Published in: Neurological Sciences | Special Issue 2/2009

Abstract

Disease-modifying treatments are now available in relapsing–remitting and secondary progressive multiple sclerosis (MS), and their beneficial effects have been shown in several clinical studies. However, as these treatments are only partially effective in halting the MS disease process and are frequently associated with side effects and suboptimal patient adherence, new oral therapeutic approaches are warranted. This review focuses on advances in current and novel oral treatment approaches for MS. Several pivotal reports have provided promising results for new oral therapies evaluating the safety and efficacy of new agents including fingolimod, fumaric acid, cladribine, teriflunomide and laquinimod.

Brinkmann V, Davis MD, Heise CE et al (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453–21473CrossRefPubMed

Brinkmann V, Cyster JG, Hla T (2004) FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 4:1019–1025CrossRefPubMed

Rosen H, Goetzel EJ (2005) Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 5:560–570CrossRefPubMed

Mandala S, Hajdu R, Bergstrom J et al (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346–349CrossRefPubMed

Kappos L, Antel J, Comi G et al (2006) Oral fingolimod (FTY720) in relapsing MS: 24-month results of the phase II study. N Engl J Med 355:1124–1140CrossRefPubMed

Loewe R, Pillinger M, De Martin R et al (2001) Dimethyl fumarate inhibits tumor-necrosis factor-induced CD62E expression in an NF-kappa B-dependent manner. J Invest Dermatol 117(69):1363–1368CrossRefPubMed

Ghoreschi K, Rocken M (2004) Immune deviation strategies in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 3(2):193–198CrossRefPubMed

Van Muiswinkel F, Kuiperij H (2005) The Nrf2-ARE signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Curr Drug Targets CNS Neurol Disord 4:267–281CrossRefPubMed

Schimrigk S, Brune N, Hellwig K et al (2006) Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 13(6):604–610CrossRefPubMed

10.

Kappos L, Miller DH, Macmanus DG et al (2006) Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing–remitting multiple sclerosis: results of a phase II study. J Neurol 253(S2):O108

11.

Carson DA, Wasson DB, Taetle R et al (1983) Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62(4):737–743PubMed

12.

Sipe JC, Romine JS, Koziol JA et al (1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344(8319):9–13CrossRefPubMed

13.

Beutler E, Sipe JC, Romine JS et al (1996) The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 93(4):1716–1720CrossRefPubMed

14.

Romine JS, Sipe JC, Koziol JA et al (1999) A double-blind, placebo-controlled, randomized trial of cladribine in relapsing–remitting multiple sclerosis. Proc Assoc Am Physicians 111(1):35–44CrossRefPubMed

15.

Rice GP, Filippi M, Comi G (2000) Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54(5):1145–1155PubMed

16.

Filippi M, Rovaris M, Rice GP et al (2000) The effect of cladribine on T(1) ‘black hole’ changes in progressive MS. J Neurol Sci 176(1):42–44CrossRefPubMed

17.

Filippi M, Rovaris M, Iannucci G et al (2000) Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55(11):1714–1718PubMed

18.

Bruneau JM, Yea CM, Spinella-Jeagle S et al (1998) Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J 336:299–303PubMed

19.

O’Connor PW, Li D, Freedmann MS et al (2006) A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66:894–900CrossRefPubMed

20.

Polman C, Barkhof F, Sandeberg-Wollheim M, Laquinimod MS Study Group et al (2005) Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64:987–991PubMed

Title: New oral drugs for multiple sclerosis
Authors: Claudio Gasperini
S. Ruggieri
Publication date: 01-10-2009
Publisher: Springer Milan
Published in: Neurological Sciences / Issue Special Issue 2/2009
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-009-0146-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

New oral drugs for multiple sclerosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2009

Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks

Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks

The pharmacovigilance program on natalizumab in Italy: 2 years of experience

Mitoxantrone: benefits and risks in multiple sclerosis patients

Safety profile of Tysabri: international risk management plan

Treatment of multiple sclerosis: role of natalizumab